12/4/2023 0 Comments Copt laba lamaTriple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis Currently the Global initiative for COPD suggests the use of long acting beta agonists (LABAs) and long acting muscarinic antagonists (LAMAs) in combination for the majority of COPD patients, thus great interest is associated with the developing of LAMA/LABA fixed combination in the maintenance treatment of stable COPD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta 2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. Source: Annual Congress 2009 - Functional insights into COPD The response to combination therapy treatment regimens in severe/difficult-to-treat asthmaĮffectiveness of combination therapy with tiotropium in COPD. Source: International Congress 2017 – COPD management In the network meta-analysis, LAMA/LABA inhalers decreased the rate of moderate to severe exacerbations compared to ICS/LABA (HR 0.86, 95 credible interval (CrI) 0.76 to 0.99), LAMA (HR 0. Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study A network meta-analysis was undertaken for dual combination inhalers compared with single-agent long-acting bronchodilators ( Oba 2018) evidence level I. Source: International Congress 2018 – Pharmacological management of COPD Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Source: International Congress 2017 – Bronchodilators and bronchoprotectorsĮfficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2018 – COPD managementĬlinical synergism of LABA/LAMA combinations in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPDĮxacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Related content which might interest you: Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |